Skip to main content
Hyloris Pharmaceuticals SA logo

Hyloris Pharmaceuticals SA — Investor Relations & Filings

Ticker · HYL ISIN · BE0974363955 LEI · 875500LZIWS7QEQE0I73 BR Manufacturing
Open in API
Filings indexed 259 across all filing types
Latest filing 2026-04-30 Annual Report
Country BE Belgium
Listing BR HYL

About Hyloris Pharmaceuticals SA

https://hyloris.com/

Hyloris Pharmaceuticals SA is a specialty biopharma company focused on innovating, reinventing, and optimizing existing medications to address unmet medical needs. The company's strategy centers on reformulating and repurposing established drugs to create value-added medicines for patients, healthcare professionals, and payors. By utilizing established regulatory pathways, such as the FDA's 505(b)(2) process, Hyloris aims to reduce development timelines, costs, and risks. The company has built a broad, patented portfolio of product candidates. Its commercialized products include Sotalol IV for the treatment of atrial fibrillation and Maxigesic® IV, a non-opioid for post-operative pain. In addition to its core focus, Hyloris also develops and commercializes high-barrier generic products.

Recent filings

Filing Released Lang Actions
HYLORIS_RA25_Rapport Annuel 2025_FR_20260430_FV.pdf
Annual Report Classification · 100% confidence The document is titled 'Rapport annuel 2025' (Annual Report 2025) for Hyloris, a pharmaceutical company. It contains detailed sections typical of an annual report, including messages from the Chairman, CEO, CFO, strategic objectives, business overview, governance, non-financial information (ESG), consolidated financial statements, and auditor's report. The length is substantial (15,000 characters), and the content includes comprehensive financial and operational information, not just an announcement or summary. The presence of detailed financial statements and management discussion confirms this is the full Annual Report. Therefore, the document fits the definition of an Annual Report (10-K).
2026-04-30 French
875500LZIWS7QEQE0I73-2025-12-31-1-fr.zip
Annual Report Classification · 100% confidence The document is titled 'Rapport annuel 2025' which translates to 'Annual Report 2025'. It contains detailed sections typical of an annual report such as messages from the Chairman, CEO, CFO, strategic objectives, business overview, governance, financial statements, and auditor's report. The text references compliance with Belgian regulatory requirements for annual management reports and includes comprehensive financial and operational information. The document length is substantial (15,000 characters) and contains actual financial data and management discussion, not just an announcement or summary. Therefore, this is a full Annual Report. FY 2025
2026-04-30 French
875500LZIWS7QEQE0I73-2025-12-31-1-fr.xhtml
Annual Report Classification · 100% confidence The document is titled "Rapport annuel 2025" (Annual Report 2025) and contains extensive content typical of a full annual report, including messages from the Chairman, CEO, CFO, detailed business overview, strategic objectives, governance, financial statements, and auditor's report. It references compliance with Belgian corporate law and includes comprehensive sections on financial performance, governance, and non-financial information. The document length is substantial (15,000 characters), indicating it is the full report rather than a brief announcement or summary. Therefore, this document fits the definition of an Annual Report (10-K). FY 2025
2026-04-30 French
Press Release_Hyloris_Update Denominator_EN_20260330.pdf
Regulatory Filings Classification · 85% confidence The document is a short press release disclosing a regulatory update on the total number of voting rights and shares (“denominator”) per the Belgian Law on disclosure of large shareholdings. It is not a financial report (10-K/IR), earnings release, or AGM material, nor does it announce an event like a merger or dividend. It is a routine statutory announcement of share/voting rights data, fitting the general regulatory filings category. Therefore it should be classified as RNS (Regulatory Filings).
2026-03-31 English
Communique Presse_Hyloris_Update Denominator_FR_20260330.pdf
Share Issue/Capital Change Classification · 75% confidence The document is a regulated press release (‘Information réglementée’) disclosing an update to the company’s share capital and total voting rights (denominator) following the issuance of new subscription rights. This is not a general earnings release, management update, or AGM material but specifically announces changes in capital structure (new subscription rights and updated share/vote count). Such notices of share issuance or capital changes fall under the Share Issue/Capital Change category (SHA).
2026-03-31 French
Hyloris_Press Release_Year Results 2025_EN_20260326_FV.pdf
Earnings Release Classification · 92% confidence The document is a press release titled “Consolidated Results 2025” and structured as a formal announcement of full‐year financial results, operational highlights, and business developments. It contains key metrics (royalties, revenues, operating income, net loss), financial tables, and descriptive commentary typical of an earnings release rather than the full statutory annual report. It is not a detailed 10-K, audit report, or regulatory notice, but rather the company’s initial public announcement of its year‐end results. Therefore, it should be classified as an Earnings Release. FY 2025
2026-03-26 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.